• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Saudi Journal of Biological Sciences >Comparative study of ticagrelor and clopidogrel in therapeutic effect of acute myocardial infarction patients undergoing percutaneous coronary intervention
【24h】

Comparative study of ticagrelor and clopidogrel in therapeutic effect of acute myocardial infarction patients undergoing percutaneous coronary intervention

机译：替卡格雷和氯吡格雷对经皮冠状动脉介入治疗急性心肌梗死患者疗效的比较研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objectives Comparison of Ticagrelor vs clopidogrel in antiplatelet therapeutic effect of acute myocardial infarction patients undergoing percutaneous coronary intervention. Methods The study focused on 2000 acute myocardial infarction patients undergoing percutaneous coronary intervention (PCI) in our hospital from January 2013 to December 2015. To reduce the formation of acute stent thrombosis caused by clopidogrel resistance, we had two options, one was to double the dosage of clopidogrel, and the other was to substitute ticagrelor for clopidogrel. Based on random number table method, the 2000 patients were divided into experimental group and control group, each containing 1,000 patients. The patients in experimental group took 180?mg ticagrelor before PCI and 90?mg ticagrelor twice a day after PCI ( Gu, 2016 ). In contrast, the patients control group took 600?mg clopidogrel before PCI and 150?mg clopidogrel once a day after PCI. Both groups were drawn 2.7?ml of fasting venous blood for platelet aggregation rate test before PCI and 2?h, 24?h, 7?days after PCI respectively. Turbidimetric method was used to measure the ADP-induced platelet aggregation rate and observe change of platelet aggregation rate and success rate. Incidence of liver and kidney malfunction and adverse actions were monitored. All patients accepted a 6-month of follow-up examination to record and compare incidences of major adverse cardiac and cerebrovascular events. The statistical results of both groups are analyzed and compared. Results The platelet aggregation rate of experimental group before PCI and 2?h, 24?h, 7?days after PCI was 59.71%?±?7.24%, 59.20%?±?7.70%, 48.66%?±?7.80% and 43.39%?±?8.28%; The control group was 58.04%?±?5.61%, 56.25%?±?6.02%, 55.68%?±?3.14%, 53.94%?±?5.30%; Comparing the platelet aggregation rate of different time, P was less than 0.05. The success rate of platelet aggregation of experimental group and control group was 80.56% and 46.86% respectively. There were significant differences between the two groups and the P was less than .05. The postoperative serum creatinine level of experimental group was higher than that in the control group (P? Conclusions Compared with clopidogrel, ticagrelor can achieve better n antiplatelet effect for patients with acute myocardial infarction undergoing percutaneous coronary intervention (PCI). It can effectively reduce the incidence of postoperative adverse cardiac and cerebrovascular events and control the rate of adverse reactions within the acceptable range.
机译：目的比较替卡格雷和氯吡格雷对经皮冠状动脉介入治疗的急性心肌梗死患者的抗血小板治疗作用。方法：本研究针对2013年1月至2015年12月在我院接受经皮冠状动脉介入治疗（PCI）的2000例急性心肌梗死患者。为了减少由氯吡格雷抵抗引起的急性支架血栓形成的发生，我们有两种选择，一种是将剂量为氯吡格雷，另一种是用替卡格雷替代氯吡格雷。根据随机数表法，将2000例患者分为实验组和对照组，每组1000例。实验组患者在PCI前服用180 mg替卡格雷或PCI后每天两次服用90mg替卡格雷（Gu，2016）。相比之下，患者对照组在PCI之前服用600？mg氯吡格雷，在PCI之后每天服用150？mg氯吡格雷。两组均在PCI前和PCI后2？h，24？h，7？天抽取2.7？ml空腹静脉血进行血小板聚集率测试。用比浊法测定ADP诱导的血小板聚集率，观察血小板聚集率和成功率的变化。监测肝肾功能衰竭和不良反应的发生率。所有患者均接受了为期6个月的随访检查，以记录和比较主要不良心脏和脑血管事件的发生率。对两组的统计结果进行分析和比较。结果PCI前，PCI后2 h，24 h，7 d实验组血小板聚集率分别为59.71％±7.24％，59.20％±7.70％，48.66％±7.80％和43.39。 ％≤±8.28％;对照组为58.04％±±5.61％，56.25％±±6.02％，55.68％±±3.14％，53.94％±±5.30％;比较不同时间的血小板聚集率，P小于0.05。实验组和对照组血小板凝集成功率分别为80.56％和46.86％。两组之间有显着性差异，P小于0.05。结论替卡格雷较经皮冠状动脉介入治疗（PCI）的急性心肌梗死患者的抗血小板作用优于氯吡格雷（P？结论）。术后不良心脏和脑血管事件的发生率并将不良反应发生率控制在可接受的范围内。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号